20% Human albumin (Hemarus Therapeutics)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug Name20% Human albumin (Hemarus Therapeutics)
Drug Alias Name20％人白蛋白静脉注射制剂Hemalb
ClassificationBiologics > Blood components
Mechanisms of ActionSerum albumin agonists
TargetsSerum albumin
Therapy Area/IndicationsHypovolemiaHypoalbuminemiaNephrotic Syndrome +[4] 
Global Approved IndicationsHypovolemiaHypoalbuminemiaNephrotic Syndrome +[4] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryIndia
Original Approved Date2015/08/01
Country/TerritoryIndia
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesHemarus Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesHemarus Therapeutics
Inactive CompaniesN/A
Active IndicationsHypovolemiaHypoalbuminemiaNephrotic Syndrome +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeB05AA01
Related LinksN/A